共 9 条
- [1] Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. White CM. Journal of Clinical Psychopharmacology . 1999
- [2] Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S)of cholesterol lowering. Pederson TR,Wilhelmsen L,Faergeman O,et al. The American Journal of Cardiology . 2000
- [3] Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. The LIPID Study Group. The Lancet . 2002
- [4] Vascular effects of HMG- CoA reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Lefer AM,Scalia R,Lefer DJ. Cardiovascular Research . 2001
- [5] Antiatherothrombotic properties of statins.Implications for cardiovascular event reduction. Rosenson RS,Tangney CC. The Journal of The American Medical Association . 1998
- [6] Pathological hypertrophy and cardiac interstitium. WEBER K T,BRILLA C G. Circulation . 1991
- [7] Differentiation of Rat Myocytes in Single Cell Cultures with and Without Proliferating Nonmyocardial Cells. Simpson P,Savion S. Circulation Research . 1982
- [8] Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Bauersachs J,Galuppo P,Fraccarollo D,et al. Circulation . 2001
- [9] Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Su SF,Hsiao CL,Chu CW,et al. The American Journal of Cardiology . 2000